NCT06001788 2025-12-03
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
Kura Oncology, Inc.
Ascentage Pharma Group Inc.
BlossomHill Therapeutics
Cogent Biosciences, Inc.